|
Acute Coronary Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This study aims to assess the cost-effectiveness in Australia of screening CYP2C19 loss-of-function (LoF) alleles to guide selection of clopidogrel or ticagrelor for individuals with acute coronary syndrome who are likely to undergo coronary stenting.
|
24279856 |
2013 |
|
Acute Coronary Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To assess the impact of different CYP2C19*2 polymorphisms on clinical outcomes and the effects of CYP2C19*2 polymorphism on predicting clinical outcomes in association with classic risk factors in patients with acute coronary syndromes (ACS).
|
21778720 |
2011 |
|
Acute Coronary Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Financial Analysis of CYP2C19 Genotyping in Patients Receiving Dual Antiplatelet Therapy Following Acute Coronary Syndrome and Percutaneous Coronary Intervention.
|
26108379 |
2015 |
|
Acute Coronary Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Genetic polymorphisms of CYP2C19 2 and ABCB1 C3435T affect the pharmacokinetic and pharmacodynamic responses to clopidogrel in 401 patients with acute coronary syndrome.
|
25542807 |
2015 |
|
Acute Coronary Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Effects of coexisting polymorphisms of CYP2C19 and P2Y12 on clopidogrel responsiveness and clinical outcome in patients with acute coronary syndromes undergoing stent-based coronary intervention.
|
23506580 |
2013 |
|
Acute Coronary Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Effect of cytochrome P450 2C19 polymorphism on adverse cardiovascular events after drug-eluting stent implantation in a large Hakka population with acute coronary syndrome receiving clopidogrel in southern China.
|
29243114 |
2018 |
|
Acute Coronary Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The present study was designed to evaluate the benefit of tailored therapy with a higher maintenance dose according to CYP2C19 genotypes in patients identified as nonresponders who underwent percutaneous coronary intervention for non-ST-segment elevation acute coronary syndromes.
|
21803320 |
2011 |
|
Acute Coronary Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
This relationship was first described in subjects after acute coronary syndrome due to the interference of proton pump inhibitors in the cytochrome P450 2C19 and the conversion of clopidogrel to its active metabolite.
|
29804887 |
2018 |
|
Acute Coronary Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Patients with recent acute coronary syndrome or percutaneous coronary intervention prescribed clopidogrel were offered CYP2C19 testing.
|
24192573 |
2013 |
|
Acute Coronary Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Genetic Polymorphism of CYP2C19 and Inhibitory Effects of Ticagrelor and Clopidogrel Towards Post-Percutaneous Coronary Intervention (PCI) Platelet Aggregation in Patients with Acute Coronary Syndromes.
|
27977637 |
2016 |
|
Acute Coronary Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
CYP2C19*2 and Other Allelic Variants Affecting Platelet Response to Clopidogrel Tested by Thrombelastography in Patients with Acute Coronary Syndrome.
|
26265611 |
2015 |
|
Acute Coronary Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Ticagrelor is a more efficacious treatment for acute coronary syndromes than is clopidogrel, irrespective of CYP2C19 and ABCB1 polymorphisms.
|
20801498 |
2010 |
|
Acute Coronary Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The CYP2C19 genotype is a predictor of adverse cardiovascular events in acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI) treated with clopidogrel.
|
23137413 |
2013 |
|
Acute Coronary Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therapeutic guidelines recommend that CYP2C19 intermediate and poor metabolizers with acute coronary syndromes undergoing percutaneous coronary intervention receive an alternative antiplatelet therapy; however, genotype-guided therapy is not a standard recommendation for neurovascular conditions.
|
31128980 |
2019 |
|
Acute Coronary Syndrome
|
0.100 |
GeneticVariation
|
disease |
LHGDN |
This study was conducted to analyze, in 603 patients with non-ST elevation acute coronary syndromes, the effect of CYP3A4, CYP3A5, and CYP2C19 gene polymorphisms on clopidogrel response and post-treatment platelet reactivity assessed by adenosine diphosphate (ADP)-induced platelet aggregation, vasodilator-stimulated phosphoprotein phosphorylation index, and ADP-induced P-selectin expression.
|
18394438 |
2008 |
|
Acute Coronary Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
We sought to assess the relationships between platelet reactivity at different time points, CYP2C19*2 and ABCB1 status and clinical outcomes in patients with acute coronary syndromes (ACS).
|
23148794 |
2013 |
|
Acute Coronary Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The cost effectiveness of genetic testing for CYP2C19 variants to guide thienopyridine treatment in patients with acute coronary syndromes: a New Zealand evaluation.
|
22974536 |
2012 |
|
Acute Coronary Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
This research evaluated the frequency of variant alleles in the genes coding for CYP3A4, CYP3A5, CYP2C9, and CYP2C19 enzymes in patients on clopidogrel therapy and experiencing repeat acute coronary syndrome (ACS) compared to a control group with a matching ethnic composition.
|
19337788 |
2009 |
|
Acute Coronary Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
CYP2C19 polymorphisms in acute coronary syndrome patients undergoing clopidogrel therapy in Zhengzhou population.
|
27323099 |
2016 |
|
Acute Coronary Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To investigate the prevalence and prognostic impact of the CYP2C19*2 allele in a local acute coronary syndrome (ACS) population.
|
22377481 |
2012 |
|
Acute Coronary Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Therefore, the present study was designed to investigate the impact of CYP2C19 loss-of-function point-of-care (POC) genotyping in patients presenting with acute coronary syndromes (ACS) and treated with dual antiplatelet therapy in the emergency setting.
|
24856643 |
2014 |
|
Acute Coronary Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Dual Antiplatelet Therapy Guided by CYP2C19 Polymorphisms after Implantation of Second-Generation Drug-Eluting Stents for Management of Acute Coronary Syndrome.
|
29279531 |
2018 |
|
Acute Coronary Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
CYP2C19 genotype plus platelet reactivity-guided antiplatelet therapy in acute coronary syndrome patients: a decision analysis.
|
26398625 |
2015 |
|
Acute Coronary Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Combination of the CYP2C19 metabolizer and the GRACE risk score better predicts the long-term major adverse cardiac events in acute coronary syndrome undergoing percutaneous coronary intervention.
|
30193195 |
2018 |
|
Acute Coronary Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
For the development of a risk score for better prediction of RPA, CYP2C19*2 genotype and previously identified nongenetic risk factors (age >65 years, Type 2 diabetes mellitus, decreased left ventricular function, renal failure and acute coronary syndrome) were analyzed.
|
18781853 |
2008 |